Additionally, HU308, via the modulation of CB2 receptors, was shown to reduce DSS-induced colitis by inhibiting the nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inflammasome in macrophages [42]. Here, NLRP3 is linked to colitis.